Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
Generate Biomedicines states that its AI-enabled Generate Platform is a tight and fully-integrated loop (design–build–test–learn) aimed to create proprietary, therapeutically relevant data and differentiated molecular solutions. The company claims that its therapeutic potential has been demonstrated by successfully progressing three computationally engineered proteins into human clinical testing, the most advanced of which is GB-0895, an investigational long-acting anti-thymic stromal lymphopoietin (“TSLP”) monoclonal antibody, which is enrolling patients in pivotal Phase 3 clinical trials for severe asthma.
The Somerville, MA-based company was founded in 2018 and plans to list on the Nasdaq under the symbol GENB. Generate Biomedicines filed confidentially on December 23, 2025. Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor Fitzgerald are the joint bookrunners on the deal.
